文献速递眼底病与葡萄膜炎

接受免疫调节治疗的非感染性葡萄膜炎结核免疫反应患者的全身与眼部结局:病例对照研究

Systemic and ocular outcomes in TB-immunoreactive patients receiving immunomodulatory therapy for non-infectious uveitis: a case-control study.
PubMed 文献 · Br J Ophthalmol · 2024-12-17

该病例对照研究回顾性比较了接受常规免疫调节治疗至少6个月的非感染性葡萄膜炎患者中,有结核免疫反应(病例)与无结核免疫反应(对照)者的全身和眼部结局。结果显示,病例组1例出现新发结核,对照组无新发结核,全身结核再激活的绝对风险增加为0.028(95%CI 0.005至0.051),需伤害人数为36;两组持续或复发性眼内炎症发生率相当(病例组18/36 vs 对照组35/70,p=1.0)。结论认为,在结核免疫反应的非感染性葡萄膜炎患者中,常规免疫调节治疗的全身结核再激活风险极低,且对眼部结局无额外不利影响。

要点

  • 病例组1例出现新发肺结核或肺外结核,对照组无新发结核。
  • 全身结核再激活绝对风险增加0.028(95%CI 0.005至0.051),需伤害人数36。
  • 持续或复发性眼内炎症发生率两组相当(病例组18/36 vs 对照组35/70,p=1.0)。

核心结论

  • 在结核免疫反应的非感染性葡萄膜炎患者中,常规免疫调节治疗的全身结核再激活风险极低,且对眼部结局无额外不利影响。

研究设计与样本

  • 回顾性病例对照研究,纳入接受常规免疫调节治疗至少6个月的非感染性葡萄膜炎患者,按有无结核免疫反应(结核菌素皮肤试验±干扰素γ释放试验)分为病例组和对照组,排除既往或同时接受抗结核治疗者。
  • 共纳入36例病例和70例对照(性别匹配和年龄匹配)。

主要发现

  • 病例组1例出现新发肺结核或肺外结核,对照组无新发结核。
  • 基于该结局,全身结核再激活的绝对风险增加为0.028(95%CI 0.005至0.051),需伤害人数为36。
  • 免疫调节治疗期间持续或复发性(加重≥2级)眼内炎症发生率两组相当:病例组18/36 vs 对照组35/70,p=1.0。
  • 复发时解剖部位改变在病例组未见,对照组有6例(p=0.15)。
  • 两组均未发现新的局灶性脉络膜视网膜病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB)-immunoreactivity, measured in vivo (tuberculin skin test (TST)) or in vitro (interferon gamma release assay (IGRA)), can be found in latent, active or even following clearance of TB infection. In this case-control study, we compared the systemic and ocular outcomes between patients with or without TB-immunoreactivity, who received immunomodulatory therapy (IMT) for non-infectious uveitis. METHODS: We retrospectively reviewed charts of patients with (cases) or without (controls) TB-immunoreactivity (TST±IGRA), who received conventional IMT for ≥6 months, for the treatment of non-infectious uveitis. Patients who received prior or concomitant anti-TB therapy were excluded. Systemic and ocular outcomes were compared between both groups. RESULTS: 36 cases and 70 controls (gender-matched and age-matched) were included. New-onset pulmonary or extrapulmonary TB developed in one case and none of the controls. Based on this outcome, the absolute risk increase for systemic TB reactivation was noted to be 0.028 (95% CI 0.005 to 0.051) and the number needed to harm was 36. The incidence of persistent or recurrent (worsening ≥2 grades) intraocular inflammation during IMT was comparable between both groups (cases 18/36, controls 35/70, p=1.0). A change in anatomical site of presentation at recurrence was not seen in any case, but in six controls (p=0.15). No new focal chorio-retinal lesions were noted in either group. CONCLUSIONS: Conventional IMT has a very low risk of systemic TB reactivation, and no additional detrimental effect on ocular outcomes, in TB-immunoreactive patients with non-infectious uveitis.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Choudhary Balla S, Ali MH, Tyagi M, et al. Systemic and ocular outcomes in TB-immunoreactive patients receiving immunomodulatory therapy for non-infectious uveitis: a case-control study. Br J Ophthalmol. 2024. PMID: 39009421. doi:10.1136/bjo-2024-325625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。